|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-2-7
|
|
pubmed:abstractText |
A series of beta-aminoamides bearing triazolopiperazines have been discovered as potent, selective, and orally active dipeptidyl peptidase IV (DPP-4) inhibitors by extensive structure-activity relationship (SAR) studies around the triazolopiperazine moiety. Among these, compound 34b with excellent in vitro potency (IC50 = 4.3 nM) against DPP-4, high selectivity over other enzymes, and good pharmacokinetic profiles exhibited pronounced in vivo efficacy in an oral glucose tolerance test (OGTT) in lean mice. On the basis of these properties, compound 34b has been profiled in detail. Further refinement of the triazolopiperazines resulted in the discovery of a series of extremely potent compounds with subnanomolar activity against DPP-4 (42b- 49b), that is, 4-fluorobenzyl-substituted compound 46b, which is notable for its superior potency (IC50 = 0.18 nM). X-ray crystal structure determination of compounds 34b and 46b in complex with DPP-4 enzyme revealed that (R)-stereochemistry at the 8-position of triazolopiperazines is strongly preferred over (S) with respect to DPP-4 inhibition.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0022-2623
|
|
pubmed:author |
pubmed-author:BrockunierLinda LLL,
pubmed-author:EiermannGeorge JGJ,
pubmed-author:FisherMichael HMH,
pubmed-author:HeHuaibingH,
pubmed-author:KimDooseopD,
pubmed-author:KowalchickJennifer EJE,
pubmed-author:LeitingBarbaraB,
pubmed-author:LyonsKathrynK,
pubmed-author:ParmeeEmma RER,
pubmed-author:PatelSangita BSB,
pubmed-author:PetrovAleksandrA,
pubmed-author:PryorKellyann DKD,
pubmed-author:RoyRanabir SinhaRS,
pubmed-author:ScapinGiovannaG,
pubmed-author:ThornberryNancy ANA,
pubmed-author:WeberAnn EAE,
pubmed-author:WuJoseph KJK,
pubmed-author:WyvrattMatthew JMJ,
pubmed-author:ZhangBei BBB,
pubmed-author:ZhangXiaopingX,
pubmed-author:ZhuLanL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
14
|
|
pubmed:volume |
51
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
589-602
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18201067-Amides,
pubmed-meshheading:18201067-Animals,
pubmed-meshheading:18201067-Crystallography, X-Ray,
pubmed-meshheading:18201067-Dipeptidyl Peptidase 4,
pubmed-meshheading:18201067-Dipeptidyl-Peptidase IV Inhibitors,
pubmed-meshheading:18201067-Dogs,
pubmed-meshheading:18201067-Glucose Tolerance Test,
pubmed-meshheading:18201067-Haplorhini,
pubmed-meshheading:18201067-Humans,
pubmed-meshheading:18201067-Male,
pubmed-meshheading:18201067-Mice,
pubmed-meshheading:18201067-Mice, Inbred C57BL,
pubmed-meshheading:18201067-Piperazines,
pubmed-meshheading:18201067-Pyrazines,
pubmed-meshheading:18201067-Rats,
pubmed-meshheading:18201067-Stereoisomerism,
pubmed-meshheading:18201067-Structure-Activity Relationship,
pubmed-meshheading:18201067-Triazoles
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines.
|
|
pubmed:affiliation |
Merck Research Laboratories, Merck & Company Inc, Rahway, NJ 07065, USA. dooseop_kim@merck.com
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|
